Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
Introduction: Diabetes treatment has incurred financial burden. We examined the cost–utility of adding dapagliflozin to the standard treatment for treating type 2 diabetes (T2DM) with cardiovascular risk in a Thai context. Methods: A two-part model, decision tree and Markov models, was developed to...
Saved in:
Main Authors: | Chaicharn Deerochanawong, Kriengsak Vareesangthip, Dilok Piyayotai, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan |
---|---|
Other Authors: | Siriraj Hospital |
Format: | Article |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/78094 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
by: Kriengsak Vareesangthip, et al.
Published: (2022) -
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020) -
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020) -
Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
by: Vareesangthip K.
Published: (2023) -
Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
by: Deerochanawong C.
Published: (2023)